Steven F. L. van Lelyveld
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Steven F. L. van Lelyveld has a total of 279 co-authors. Here are the top co-authors by number of shared publications:
- Marco Goeijenbier
Department of Intensive Care Medicine, Spaarne Gasthuis, Haarlem, The Netherlands
7 shared publications - Amam Winkel
Spaarne Gasthuis Academy Hoofddorp The Netherlands
5 shared publications - Dirk Eggink
Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands
5 shared publications - Sjoerd M. Euser
Regional Public Health Laboratory Kennemerland, Haarlem, the Netherlands
5 shared publications - Dennis Souverein
Regional Public Health Laboratory Kennemerland, 2035 RC Haarlem, The Netherlands
4 shared publications - Jayant Kalpoe
Regional Public Health Laboratory Kennemerland, 2035 RC Haarlem, The Netherlands
4 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Wiley in Reviews in Medical Virology
- Vol. 36 (6) , e70206
Continuous Intravenous Acyclovir as Outpatient Parenteral Antimicrobial Therapy for HSV and VZV Neurological Infections: A Case Series With Pharmacokinetic and Cost Evaluation, and Review of Literature
Varicella zoster virus (VZV) and herpes simplex virus (HSV) are major causes of viral meningitis and encephalitis. Standard intermittent intravenous acyclovir requires hospitalisation, reducing patient comfort and prolonging admissions. Continuous infusion may maintain therapeutic plasma and cerebrospinal fluid (CSF) concentrations while enabling treatment through Outpatient Parenteral Antimicrobial Therapy (OPAT). Objectives to evaluate the feasibility, pharmacokinetic target attainment, and cost reduction of continuous intravenous acyclovir for HSV and VZV neurological infections in an OPAT setting. We conducted a case series of eight patients with HSV or VZV neurological infections who received continuous intravenous acyclovir through our OPAT programme after initial hospital‐based therapy. Steady‐state plasma concentrations were measured to assess pharmacokinetic target attainment. Costs were calculated based on daily costs of discontinued inpatient care and OPAT. Existing literature on continuous intravenous acyclovir and acyclovir in OPAT was reviewed. No persistent complications associated with continuous intravenous acyclovir administration were observed. All patients completed treatment with good clinical responses; one had persistent ptosis, and another developed postherpetic neuralgia. Acyclovir plasma concentrations remained above the therapeutic threshold in all seven measured cases, suggesting adequate CSF exposure. Hospital admissions were shortened, with no readmissions. The acyclovir OPAT programme led to cost savings of 3486 EUR per patient. Despite this small case series, continuous intravenous acyclovir appears to be feasible for treating HSV and VZV neurological infections in an OPAT setting, with potential benefits in patient comfort, healthcare costs, and hospital resource utilization. Larger studies are warranted to assess safety and efficacy.
- 29 September 2026
- Published by Wiley in Reviews in Medical Virology
- Vol. 36 (6) , e70206
Open AccessContinuous Intravenous Acyclovir as Outpatient Parenteral Antimicrobial Therapy for HSV and VZV Neurological Infections: A Case Series With Pharmacokinetic and Cost Evaluation, and Review of Literature
Varicella zoster virus (VZV) and herpes simplex virus (HSV) are major causes of viral meningitis and encephalitis. Standard intermittent intravenous acyclovir requires hospitalisation, reducing patient comfort and prolonging admissions. Continuous infusion may maintain therapeutic plasma and cerebrospinal fluid (CSF) concentrations while enabling treatment through Outpatient Parenteral Antimicrobial Therapy (OPAT). Objectives to evaluate the feasibility, pharmacokinetic target attainment, and cost reduction of continuous intravenous acyclovir for HSV and VZV neurological infections in an OPAT setting. We conducted a case series of eight patients with HSV or VZV neurological infections who received continuous intravenous acyclovir through our OPAT programme after initial hospital‐based therapy. Steady‐state plasma concentrations were measured to assess pharmacokinetic target attainment. Costs were calculated based on daily costs of discontinued inpatient care and OPAT. Existing literature on continuous intravenous acyclovir and acyclovir in OPAT was reviewed. No persistent complications associated with continuous intravenous acyclovir administration were observed. All patients completed treatment with good clinical responses; one had persistent ptosis, and another developed postherpetic neuralgia. Acyclovir plasma concentrations remained above the therapeutic threshold in all seven measured cases, suggesting adequate CSF exposure. Hospital admissions were shortened, with no readmissions. The acyclovir OPAT programme led to cost savings of 3486 EUR per patient. Despite this small case series, continuous intravenous acyclovir appears to be feasible for treating HSV and VZV neurological infections in an OPAT setting, with potential benefits in patient comfort, healthcare costs, and hospital resource utilization. Larger studies are warranted to assess safety and efficacy.
- Open Access
- 30 August 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (17) , 2786
Clinician-Reported Respiratory Viral Testing and Intended Management of Community-Acquired Respiratory Viral Infections in Haematology and Haematopoietic Cell Transplantation: An International Exploratory Survey
Background: Community-acquired respiratory viruses (CARVs) cause significant morbidity and mortality in patients with haematological malignancies and those undergoing haematopoietic cell transplantation (HCT). Despite this, clinical management remains variable. This study evaluated clinicians’ awareness, diagnostic practices, and treatment approaches to major respiratory viruses in this high-risk population. Methods: An international electronic survey using non-probability convenience sampling was conducted among haematology, oncology, intensive care and emergency medicine physicians. Four real-life clinical cases were converted into standardised vignettes covering human metapneumovirus (HMPV), respiratory syncytial virus (RSV), human parainfluenza virus (HPIV) and influenza A virus (IAV). The questionnaire assessed reported testing strategies and intended management, including antiviral and immunoprophylactic interventions. Responses were analysed descriptively; no inferential between-group comparisons were performed. Results: Ninety-eight clinicians from 26 countries responded. Diagnostic approaches, including testing indications and panel selection, varied among respondents. For HMPV and HPIV, respondents mainly reported supportive care, immunoglobulin replacement, and infection-control measures in the absence of established pathogen-specific interventions. RSV practice was heterogeneous: systemic ribavirin was considered by 45/96 (46.9%) respondents, including 34/96 (35.4%) when guided by an immunodeficiency score. IAV management was more consistent, with reported availability of vaccination and antiviral therapy and frequent use of post-exposure prophylaxis. Conclusions: Within this international convenience sample, clinicians reported variation in respiratory viral testing and in how results informed intended management. Because sampling was non-probability-based and respondent groups were small and unevenly distributed, the findings should not be interpreted as representative estimates of international practice. IAV testing was most consistently linked to established treatment and prevention, RSV showed greater therapeutic and preventive heterogeneity, and HMPV/HPIV testing primarily informed infection control, monitoring and antimicrobial stewardship.
- 30 August 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (17) , 2786
Open AccessClinician-Reported Respiratory Viral Testing and Intended Management of Community-Acquired Respiratory Viral Infections in Haematology and Haematopoietic Cell Transplantation: An International Exploratory Survey
Background: Community-acquired respiratory viruses (CARVs) cause significant morbidity and mortality in patients with haematological malignancies and those undergoing haematopoietic cell transplantation (HCT). Despite this, clinical management remains variable. This study evaluated clinicians’ awareness, diagnostic practices, and treatment approaches to major respiratory viruses in this high-risk population. Methods: An international electronic survey using non-probability convenience sampling was conducted among haematology, oncology, intensive care and emergency medicine physicians. Four real-life clinical cases were converted into standardised vignettes covering human metapneumovirus (HMPV), respiratory syncytial virus (RSV), human parainfluenza virus (HPIV) and influenza A virus (IAV). The questionnaire assessed reported testing strategies and intended management, including antiviral and immunoprophylactic interventions. Responses were analysed descriptively; no inferential between-group comparisons were performed. Results: Ninety-eight clinicians from 26 countries responded. Diagnostic approaches, including testing indications and panel selection, varied among respondents. For HMPV and HPIV, respondents mainly reported supportive care, immunoglobulin replacement, and infection-control measures in the absence of established pathogen-specific interventions. RSV practice was heterogeneous: systemic ribavirin was considered by 45/96 (46.9%) respondents, including 34/96 (35.4%) when guided by an immunodeficiency score. IAV management was more consistent, with reported availability of vaccination and antiviral therapy and frequent use of post-exposure prophylaxis. Conclusions: Within this international convenience sample, clinicians reported variation in respiratory viral testing and in how results informed intended management. Because sampling was non-probability-based and respondent groups were small and unevenly distributed, the findings should not be interpreted as representative estimates of international practice. IAV testing was most consistently linked to established treatment and prevention, RSV showed greater therapeutic and preventive heterogeneity, and HMPV/HPIV testing primarily informed infection control, monitoring and antimicrobial stewardship.
- Open Access
- 26 May 2026
- Published by Elsevier in The Lancet Microbe
- p. 101429
Improving prediction of future Mycoplasma pneumoniae epidemics using data-driven transmission models
- 26 May 2026
- Published by Elsevier in The Lancet Microbe
- p. 101429
Open AccessImproving prediction of future Mycoplasma pneumoniae epidemics using data-driven transmission models
- 18 December 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (6) , 997-1006
Incidence of Community-acquired Pneumonia and Herpes Zoster in People With HIV Based on CD4 Count and Age in the Current Antiretroviral Therapy Era: A Longitudinal Cohort Study
Background: People with HIV (PWH) using antiretroviral therapy (ART) remain at increased risk for infections such as community-acquired pneumonia (CAP) and herpes zoster (HZ), for which vaccinations are recommended. However, these recommendations do not consider the combined effects of age, CD4 count, and duration of ART on infection risk. We assessed how these factors influence CAP and HZ incidence to better tailor vaccination strategies. Methods: We used data from a nationwide cohort study including all PWH aged ≥18 years in care between 2010 and 2023. All documented CAP and HZ episodes were included, and incidence rates were calculated per 1000 person-years of follow-up (PYFU), stratified by age, CD4 count, and ART duration. Results: Community-acquired pneumonia and herpes zoster incidence rates were highest in PWH with CD4 ≤ 200 cells/µL, ranging from 34 to 107/1000 PYFU for CAP and 9 to 63/1000 PYFU for HZ, depending on age. In those with CD4 ≥ 500 cells/µL and ≥1 year on ART, incidence rates ranged from 5 to 20/1000 PYFU for CAP and 4 to 5/1000 PYFU for HZ, depending on age. Conclusions: Incidence rates are the highest in PWH with CD4 counts ≤200 cells/µL and/or not on ART, whereas PWH with CD4 counts ≥500 and ≥1 year on ART have a risk of CAP and HZ comparable to that of the general population. These findings support aligning vaccine recommendations for PWH on long-term suppressive ART with immune reconstitution with those for the general population, while HIV-specific vaccination strategies may remain most relevant for individuals with virological failure and/or poor immune reconstitution.
- 18 December 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (6) , 997-1006
Incidence of Community-acquired Pneumonia and Herpes Zoster in People With HIV Based on CD4 Count and Age in the Current Antiretroviral Therapy Era: A Longitudinal Cohort Study
Background: People with HIV (PWH) using antiretroviral therapy (ART) remain at increased risk for infections such as community-acquired pneumonia (CAP) and herpes zoster (HZ), for which vaccinations are recommended. However, these recommendations do not consider the combined effects of age, CD4 count, and duration of ART on infection risk. We assessed how these factors influence CAP and HZ incidence to better tailor vaccination strategies. Methods: We used data from a nationwide cohort study including all PWH aged ≥18 years in care between 2010 and 2023. All documented CAP and HZ episodes were included, and incidence rates were calculated per 1000 person-years of follow-up (PYFU), stratified by age, CD4 count, and ART duration. Results: Community-acquired pneumonia and herpes zoster incidence rates were highest in PWH with CD4 ≤ 200 cells/µL, ranging from 34 to 107/1000 PYFU for CAP and 9 to 63/1000 PYFU for HZ, depending on age. In those with CD4 ≥ 500 cells/µL and ≥1 year on ART, incidence rates ranged from 5 to 20/1000 PYFU for CAP and 4 to 5/1000 PYFU for HZ, depending on age. Conclusions: Incidence rates are the highest in PWH with CD4 counts ≤200 cells/µL and/or not on ART, whereas PWH with CD4 counts ≥500 and ≥1 year on ART have a risk of CAP and HZ comparable to that of the general population. These findings support aligning vaccine recommendations for PWH on long-term suppressive ART with immune reconstitution with those for the general population, while HIV-specific vaccination strategies may remain most relevant for individuals with virological failure and/or poor immune reconstitution.
- Open Access
- 6 December 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (12) , e70727
Persistent Symptoms in SARS‐CoV‐2‐Infected and Non‐Infected Household Members: A Prospective Cohort Study
This prospective study assessed the prevalence, type, and consequences of persistent symptoms following a nonhospitalized SARS‐CoV‐2 infection by comparing infected and noninfected children and adults of Dutch households. Two comparable prospective household studies were conducted during two pandemic phases. At baseline, all household members were tested for SARS‐CoV‐2 with 10 consecutive saliva samples during a 6‐week period using RT‐PCR. Questionnaires assessing persistent symptoms, health‐related quality of life (HRQoL), anxiety, and depressive symptoms were collected at 6 and 12 months. Of the 297 included participants (median age 34 years, IQR 12–48), 201 (67.7%) tested positive for SARS‐CoV‐2. At 6 months, only one child reported persistent symptoms. SARS‐CoV‐2‐infected adults (> 18 years) reported more pulmonary symptoms (15.2% vs. 3.4%, p = 0.023), and tended to report more fatigue (12.8% vs. 3.4%, p = 0.061) and exertion‐related symptoms (8.8% vs. 1.7%, p = 0.107) compared to the negative adults. Adult participants with persistent symptoms reported decreased HRQoL and increased anxiety and depressive symptoms. This study found that SARS‐CoV‐2‐positive adults tended to have higher prevalence of respiratory symptoms, fatigue, and exertion‐related symptoms 6 months after SARS‐CoV‐2 infection, whereas children rarely reported persistent symptoms. Persistent symptoms were associated with a reduced HRQoL and increased anxiety and depression.
- 6 December 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (12) , e70727
Open AccessPersistent Symptoms in SARS‐CoV‐2‐Infected and Non‐Infected Household Members: A Prospective Cohort Study
This prospective study assessed the prevalence, type, and consequences of persistent symptoms following a nonhospitalized SARS‐CoV‐2 infection by comparing infected and noninfected children and adults of Dutch households. Two comparable prospective household studies were conducted during two pandemic phases. At baseline, all household members were tested for SARS‐CoV‐2 with 10 consecutive saliva samples during a 6‐week period using RT‐PCR. Questionnaires assessing persistent symptoms, health‐related quality of life (HRQoL), anxiety, and depressive symptoms were collected at 6 and 12 months. Of the 297 included participants (median age 34 years, IQR 12–48), 201 (67.7%) tested positive for SARS‐CoV‐2. At 6 months, only one child reported persistent symptoms. SARS‐CoV‐2‐infected adults (> 18 years) reported more pulmonary symptoms (15.2% vs. 3.4%, p = 0.023), and tended to report more fatigue (12.8% vs. 3.4%, p = 0.061) and exertion‐related symptoms (8.8% vs. 1.7%, p = 0.107) compared to the negative adults. Adult participants with persistent symptoms reported decreased HRQoL and increased anxiety and depressive symptoms. This study found that SARS‐CoV‐2‐positive adults tended to have higher prevalence of respiratory symptoms, fatigue, and exertion‐related symptoms 6 months after SARS‐CoV‐2 infection, whereas children rarely reported persistent symptoms. Persistent symptoms were associated with a reduced HRQoL and increased anxiety and depression.
- Open Access
- 2 November 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (11) , 1103
The Impact of a Structured Outpatient Parenteral Antimicrobial Therapy (OPAT) Programme on Quality of Care, Optimisation of Antimicrobial Use, and Healthcare Costs: A Retrospective Cohort Study
Background/Objectives: In 2022, Spaarne Gasthuis hospital implemented an outpatient parenteral antimicrobial therapy (OPAT) programme, including mandatory infectious disease (ID) specialist assessment and integrated structured workflow, aiming to improve quality of care, optimize antimicrobial use, and reduce healthcare costs. Our objective was to evaluate the impact of the OPAT programme on patient outcomes (IV duration, clinical response, adverse clinical outcomes, timely peripherally inserted central catheter (PICC) removal), antimicrobial stewardship parameters, and healthcare costs. Methods: This retrospective before–after cohort study used electronic health record data to compare patients treated with outpatient parenteral antimicrobial therapy before (2019) and after (August 2022–December 2024) OPAT programme implementation. Using linear and logistic regression analyses, the association between the independent variable (pre-OPAT vs. OPAT) and outcomes were assessed and adjusted for potential confounders (sex, age, department, primary and additional indications). Cost analysis was performed, and ID specialist-recommended therapy adjustments were evaluated. Results: In total, 529 patients were included: 118 in the pre-OPAT group, and 411 in the OPAT group. In 36.3% of OPAT cases, therapy was adjusted, thereby optimizing antimicrobial stewardship. The OPAT programme was associated with significantly shorter IV therapy duration of 13.97 (mean) days (95%CI −9.15–−18.79; p < 0.001), significantly less meropenem use (p < 0.001), and significantly less adverse clinical outcomes (OR 0.58, 95%CI 0.37–0.92; p = 0.021), whereas no significant difference was found in clinical response (OR 1.22; 95%CI 0.67–2.32; p = 0.527). The programme led to cost savings of 3.343 EUR per patient. Conclusions: The OPAT programme optimized antimicrobial use and reduced IV therapy duration, adverse clinical outcomes, and healthcare costs.
- 2 November 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (11) , 1103
Open AccessThe Impact of a Structured Outpatient Parenteral Antimicrobial Therapy (OPAT) Programme on Quality of Care, Optimisation of Antimicrobial Use, and Healthcare Costs: A Retrospective Cohort Study
Background/Objectives: In 2022, Spaarne Gasthuis hospital implemented an outpatient parenteral antimicrobial therapy (OPAT) programme, including mandatory infectious disease (ID) specialist assessment and integrated structured workflow, aiming to improve quality of care, optimize antimicrobial use, and reduce healthcare costs. Our objective was to evaluate the impact of the OPAT programme on patient outcomes (IV duration, clinical response, adverse clinical outcomes, timely peripherally inserted central catheter (PICC) removal), antimicrobial stewardship parameters, and healthcare costs. Methods: This retrospective before–after cohort study used electronic health record data to compare patients treated with outpatient parenteral antimicrobial therapy before (2019) and after (August 2022–December 2024) OPAT programme implementation. Using linear and logistic regression analyses, the association between the independent variable (pre-OPAT vs. OPAT) and outcomes were assessed and adjusted for potential confounders (sex, age, department, primary and additional indications). Cost analysis was performed, and ID specialist-recommended therapy adjustments were evaluated. Results: In total, 529 patients were included: 118 in the pre-OPAT group, and 411 in the OPAT group. In 36.3% of OPAT cases, therapy was adjusted, thereby optimizing antimicrobial stewardship. The OPAT programme was associated with significantly shorter IV therapy duration of 13.97 (mean) days (95%CI −9.15–−18.79; p < 0.001), significantly less meropenem use (p < 0.001), and significantly less adverse clinical outcomes (OR 0.58, 95%CI 0.37–0.92; p = 0.021), whereas no significant difference was found in clinical response (OR 1.22; 95%CI 0.67–2.32; p = 0.527). The programme led to cost savings of 3.343 EUR per patient. Conclusions: The OPAT programme optimized antimicrobial use and reduced IV therapy duration, adverse clinical outcomes, and healthcare costs.
- Open Access
Clinical Characteristics and Outcomes of ICU Patients During the First Post-COVID-19 2023–2024 Influenza Season in The Netherlands
Background: Influenza can cause severe complications, especially in patients with specific risk factors or comorbidities associated with poor outcomes. Some patients are at increased risk of a complicated disease course, including secondary infections, ICU admission, and the need for mechanical ventilation. The first post–COVID-19 seasonal influenza season placed a substantial burden on Dutch ICUs. This study investigates the disease course and outcomes of ICU patients with influenza. Methods: A retrospective influenza registry study was conducted across 34 Dutch ICUs, including patients aged 18 and older admitted to the ICU with a positive influenza RT-PCR test, between 1 November 2023 and 17 March 2024. Data on demographic information, medical history, clinical symptoms, laboratory and imaging results, parameters of mechanical ventilation, additional treatments, length of hospital stay, and mortality was retrieved from the electronic patient record. Results: A total of 498 patients were included in the study. The median age was 64 (IQR: 55–72) years and 58.8% of the patients were men. The most common comorbidities were cardiovascular disease (34.1%), chronic obstructive pulmonary disease (COPD) (31.5%), and diabetes (22.3%). Bacterial co-infections were present in 37.6% of the patients. Invasive mechanical ventilation (IMV) was necessary in 46.0% of patients, 38.0% of those requiring IMV were treated in prone position. A substantial mortality rate was observed, with an ICU mortality rate of 21.9% and an additional hospital mortality rate of 5.2%. Conclusion: This study described the characteristics and course of disease of all patients with laboratory-confirmed influenza infection admitted to one of the 34 participating Dutch ICUs between November 2023 and March 2024. The major findings of this study are the substantial mortality rate, a high proportion of patients with bacterial co-infections, and a significant percentage of patients requiring IMV and prone position ventilation. Finally, patients without comorbidities that were admitted to the ICU with an influenza virus infection showed severe disease parameters but had a lower mortality than patients with comorbidities.
Open AccessClinical Characteristics and Outcomes of ICU Patients During the First Post-COVID-19 2023–2024 Influenza Season in The Netherlands
Background: Influenza can cause severe complications, especially in patients with specific risk factors or comorbidities associated with poor outcomes. Some patients are at increased risk of a complicated disease course, including secondary infections, ICU admission, and the need for mechanical ventilation. The first post–COVID-19 seasonal influenza season placed a substantial burden on Dutch ICUs. This study investigates the disease course and outcomes of ICU patients with influenza. Methods: A retrospective influenza registry study was conducted across 34 Dutch ICUs, including patients aged 18 and older admitted to the ICU with a positive influenza RT-PCR test, between 1 November 2023 and 17 March 2024. Data on demographic information, medical history, clinical symptoms, laboratory and imaging results, parameters of mechanical ventilation, additional treatments, length of hospital stay, and mortality was retrieved from the electronic patient record. Results: A total of 498 patients were included in the study. The median age was 64 (IQR: 55–72) years and 58.8% of the patients were men. The most common comorbidities were cardiovascular disease (34.1%), chronic obstructive pulmonary disease (COPD) (31.5%), and diabetes (22.3%). Bacterial co-infections were present in 37.6% of the patients. Invasive mechanical ventilation (IMV) was necessary in 46.0% of patients, 38.0% of those requiring IMV were treated in prone position. A substantial mortality rate was observed, with an ICU mortality rate of 21.9% and an additional hospital mortality rate of 5.2%. Conclusion: This study described the characteristics and course of disease of all patients with laboratory-confirmed influenza infection admitted to one of the 34 participating Dutch ICUs between November 2023 and March 2024. The major findings of this study are the substantial mortality rate, a high proportion of patients with bacterial co-infections, and a significant percentage of patients requiring IMV and prone position ventilation. Finally, patients without comorbidities that were admitted to the ICU with an influenza virus infection showed severe disease parameters but had a lower mortality than patients with comorbidities.
- Open Access
- 9 May 2025
- Published by Elsevier in Journal of Infection
- Vol. 90 (6) , 106501
Impact of co-infection with SARS-CoV-2 and other respiratory viruses on illness: Pooled analyses of 11 COVID-19 cohorts
- 9 May 2025
- Published by Elsevier in Journal of Infection
- Vol. 90 (6) , 106501
Open AccessImpact of co-infection with SARS-CoV-2 and other respiratory viruses on illness: Pooled analyses of 11 COVID-19 cohorts
- 17 January 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 231 (4) , 940-945
Shortened SARS-CoV-2 Viral RNA Shedding in Saliva During Early Omicron Compared to Wild-Type Pandemic Phase
This study compared the dynamics of SARS-CoV-2 viral shedding in saliva between wild-type virus–infected and Omicron-infected household cohorts. Preexisting immunity in participants likely shortens the viral RNA shedding duration and lowers viral load peaks. Frequent saliva sampling can be a convenient tool to study viral load dynamics.
- 17 January 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 231 (4) , 940-945
Shortened SARS-CoV-2 Viral RNA Shedding in Saliva During Early Omicron Compared to Wild-Type Pandemic Phase
This study compared the dynamics of SARS-CoV-2 viral shedding in saliva between wild-type virus–infected and Omicron-infected household cohorts. Preexisting immunity in participants likely shortens the viral RNA shedding duration and lowers viral load peaks. Frequent saliva sampling can be a convenient tool to study viral load dynamics.
- 8 November 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 231 (3) , 653-664
Lower Levels of Household Transmission of SARS-CoV-2 Omicron Variant of Concern vs Wild Type: An Interplay Between Transmissibility and Immune Status
Background: Knowledge of SARS-CoV-2 household transmission dynamics guides infection control and vaccination measures. This household cohort study prospectively assessed the impact of the Omicron BA.2 variant and immunity on household transmission using dense saliva sampling and sequence analysis. Method: Households consisting of a polymerase chain reaction–confirmed index and at least 2 household members were enrolled in March and April 2022 during the Omicron BA.2 wave in the Netherlands. SARS-CoV-2 polymerase chain reaction was performed on 10 consecutive saliva samples. Serum antibodies were measured at baseline and day 42. Household and per-person secondary attack rates (SARs) were calculated to measure transmission. Whole genome sequencing was performed for phylogenetic analysis, followed by sensitivity analysis, to correct for multiple household introductions and index definition. Results were compared with the identical, early-pandemic, preimmunization predecessor study. Results: Sixty-seven households were included, consisting of 241 individuals (median age, 33.0 years; IQR, 12.0–46.0). Maximum household SAR was 59.7% and per-person SAR 41.5%. Pediatric index cases were more likely to transmit. Transmission was negatively affected by household members’ immunity. Phylogenetic analysis showed multiple introductions in 4 households. Sensitivity analysis resulted in a minimal household SAR of 51.0% and per-person SAR of 28.5%. Conclusions: The Omicron BA.2 variant is highly transmissible within households. However, the transmission rate is lower when compared with previous studies with other SARS-CoV-2 variants, highlighting the effect of immunity. Regardless of immune status, children have a crucial role in Omicron household transmission. Intensive sampling and phylogenetic analysis are beneficial for correctly calculating transmission rates, especially during periods of minimal behavioral restrictions.
- 8 November 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 231 (3) , 653-664
Lower Levels of Household Transmission of SARS-CoV-2 Omicron Variant of Concern vs Wild Type: An Interplay Between Transmissibility and Immune Status
Background: Knowledge of SARS-CoV-2 household transmission dynamics guides infection control and vaccination measures. This household cohort study prospectively assessed the impact of the Omicron BA.2 variant and immunity on household transmission using dense saliva sampling and sequence analysis. Method: Households consisting of a polymerase chain reaction–confirmed index and at least 2 household members were enrolled in March and April 2022 during the Omicron BA.2 wave in the Netherlands. SARS-CoV-2 polymerase chain reaction was performed on 10 consecutive saliva samples. Serum antibodies were measured at baseline and day 42. Household and per-person secondary attack rates (SARs) were calculated to measure transmission. Whole genome sequencing was performed for phylogenetic analysis, followed by sensitivity analysis, to correct for multiple household introductions and index definition. Results were compared with the identical, early-pandemic, preimmunization predecessor study. Results: Sixty-seven households were included, consisting of 241 individuals (median age, 33.0 years; IQR, 12.0–46.0). Maximum household SAR was 59.7% and per-person SAR 41.5%. Pediatric index cases were more likely to transmit. Transmission was negatively affected by household members’ immunity. Phylogenetic analysis showed multiple introductions in 4 households. Sensitivity analysis resulted in a minimal household SAR of 51.0% and per-person SAR of 28.5%. Conclusions: The Omicron BA.2 variant is highly transmissible within households. However, the transmission rate is lower when compared with previous studies with other SARS-CoV-2 variants, highlighting the effect of immunity. Regardless of immune status, children have a crucial role in Omicron household transmission. Intensive sampling and phylogenetic analysis are beneficial for correctly calculating transmission rates, especially during periods of minimal behavioral restrictions.